COFFEE REGIONAL MEDICAL CENTER

Teprotumumab−trbw (TEPEZZA®) Protocol Orders
FOR OUTPATIENT INFUSION USE ONLY

3PO

Primary Diagnoses:

Thyroid Eye Disease (TED) ICD−10: E05.00 _____

ICD−10:_____

Has patient received TEPEZZA® before? No Yes (date of last infusion:) _____

Clinical Information:

Clinical MD Notes; labs, test supporting primary diagnosis, and clearance from endocrinologist required.

Recent Lab Results including baseline glucose or other measures of glycemic control.

Negative pregnancy test results within 48 hours prior to TEPEZZA® infusion.

Patient Weight_____lbs Patient Height:_____in.

Medication Orders:

TEPEZZA® (teprotumumab−trbw)

Initiation: 10mg/kg IV (_____mg) infused over 90 minutes.
If dose < 1800 mg dilute in 0.9% Sodium Chloride solution to a total volume of 100 ml. If dose ≥ 1800 mg dilute in 0.9% Sodium Chloride solution to a total volume of 250 ml.

Maintenance:

20mg/kg IV (_____mg) infused over 90 minutes every three weeks.
If dose < 1800 mg dilute in 0.9% Sodium Chloride solution to a total volume of 100 ml.
If dose ≥ 1800 mg dilute in 0.9% Sodium Chloride solution to a total volume of 250 ml.

IV Infusion Therapy:

- Peripheral IV − start Normal Saline at KVO. Notify Pharmacy when IV access is established.
- No pre−medications necessary. Follow OP IV Therapy Infusion Reaction Protocol in the event of patient adverse reaction to medication.
- Vital Signs pre−infusion, and then at 15 minutes, and every 30 minutes during infusion, then one hour after the infusion is complete.
- A nurse to be in attendance during the first 15 minutes of infusion, and then close observation for the remainder of the 90−minute infusion.
- If patient develops flushing of face, chest tightness, chills, fever, dizziness, nausea, diaphoresis, or hypotension, stop infusion and restart normal saline. Take vital signs and notify physician and pharmacist. Monitor until condition resolves.
- Have immediately available, T B syringe, 12ml syringe, 22−gauge needles x2, Epinephrine 1:1000 x1 amp, sterile water x2, Benadryl 50mg inject x1 amp, and 3ml syringe.

PO_9286_EFR
05/10/2022

COFFEE REGIONAL MEDICAL CENTER

Teprotumumab−trbw (TEPEZZA®) Protocol Orders
FOR OUTPATIENT INFUSION USE ONLY

Patient Counseling Information:

- Advise females of reproductive potential that TEPEZZA® can cause harm to a fetus and to inform their healthcare provider of a known or suspected pregnancy.
- Educate and counsel females of reproductive potential about the need to use effective contraception prior to initiation, during treatment with TEPEZZA® and for 6 months after the last dose of TEPEZZA.
- Advise patients that TEPEZZA® may cause infusion reactions that can occur at any time. Instruct patients to recognize the signs and symptoms of infusion reaction and to contact their healthcare provider immediately for signs or symptoms of potential infusion−related reactions.
- Advise patients on the risk of inflammatory bowel disease (IBD) and to seek medical advice immediately if they experience diarrhea, with or without blood or rectal bleeding, associated with abdominal pain or cramping/colic, urgency, tenesmus, or incontinence.
- Advise patients on the risk of hyperglycemia and, if diabetic, discuss with healthcare provider to adjust glycemic control medications as appropriate. Encourage compliance with glycemic control
- Criteria to be added for Endocrinology Clearance.

Physician Signature

Date / Time